dc.contributor.author |
Schellack, Natalie
|
|
dc.contributor.author |
Padayachee, N.
|
|
dc.date.accessioned |
2023-02-07T10:06:10Z |
|
dc.date.available |
2023-02-07T10:06:10Z |
|
dc.date.issued |
2022 |
|
dc.description.abstract |
This article provides an overview of the changes that have taken place in the diagnosis and management of hypertension over the past
decade. Hypertension remains a widespread condition seen in South Africa. The approach to managing hypertension includes necessary
lifestyle modifications and a decisive, stepwise escalation process in the pharmacotherapeutic management thereof. Most guidelines are
still promoting thiazide diuretics to be the initial (first-line) drug of choice, with the addition of other suitable antihypertensive agents, if
necessary, and according to any relevant comorbid conditions. |
en_US |
dc.description.department |
Pharmacology |
en_US |
dc.description.librarian |
am2023 |
en_US |
dc.description.uri |
http://www.sapj.co.za/index.php/sapj |
en_US |
dc.identifier.citation |
Schellack, N. & Padayachee, N. 2022, 'Hypertension', SA Pharmaceutical Journal, vol. 89, no. 1, pp. 19-27. |
en_US |
dc.identifier.issn |
2221-5875 (print) |
|
dc.identifier.issn |
2220-1017 (online) |
|
dc.identifier.uri |
https://repository.up.ac.za/handle/2263/89213 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Medpharm Publications |
en_US |
dc.rights |
© Medpharm. This article is licensed under a This article is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.5 South Africa License. |
en_US |
dc.subject |
Hypertension |
en_US |
dc.subject |
Antihypertensive agents |
en_US |
dc.subject |
Fixed-dose combination therapy |
en_US |
dc.subject |
Angiotensin II-receptor blockers |
en_US |
dc.subject |
Angiotensin-converting enzyme inhibitors |
en_US |
dc.subject |
Calcium-channel blockers |
en_US |
dc.title |
Hypertension |
en_US |
dc.type |
Article |
en_US |